Eli Lilly

News

Trulicity helps SGLT-2 patients lower blood sugar

New phase 3b trial results show Lilly’s Trulicity combined with an SGLT2 inhibitor failed to show any benefits above and beyond Trulicity’s blood glucose lowering.

News

Novo's GLP-1 duel with Lilly begins as drug reimbursed in US

Oral formulation succeeds in first phase 3 trial

News

Lilly axes trial of Hanmi's arthritis drug

Lilly may decide to develop drug in other indications

Digital

South Korea flag is waving at a beautiful and peaceful sky in day time while sun is shining. 3D Rendering

South Korea hopes big data will boost life sciences industry

South Korea is to build a comprehensive database of genetic and biometric data from 10 million people, in a bid to boost its pharma and biotech industry.

News

Closeup of X-ray photography of human brain

Doubts over BACE drugs after Merck ends Alzheimer's trial

Decision comes a year after Merck axed EPOCH verubecestat trial

News

Lilly aims for new indication for Taltz

Eli Lilly is hoping new data from its Taltz (ixekizumab) could give it another potentially lucrative indication and put pressure on Novartis’ rival IL-17a drug, Cosentyx.

Trulicity helps SGLT-2 patients lower blood sugar

Novo's GLP-1 duel with Lilly begins as drug reimbursed in US

Lilly axes trial of Hanmi's arthritis drug

South Korea hopes big data will boost life sciences industry

Doubts over BACE drugs after Merck ends Alzheimer's trial

Lilly aims for new indication for Taltz

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Eli Lilly

Editor's Picks